The Biospecimen Preanalytical Variables Program: A Multiassay Comparison of Effects of Delay to Fixation and Fixation Duration on Nucleic Acid Quality.

Colonic Neoplasms / chemistry Cryopreservation / methods DNA / analysis Female Humans Kidney Neoplasms / chemistry National Cancer Institute (U.S.) Ovarian Neoplasms / chemistry Paraffin Embedding / methods Pre-Analytical Phase / methods Quality Control RNA / analysis Real-Time Polymerase Chain Reaction Specimen Handling / methods Time Factors Tissue Fixation / methods United States

Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 21 2 2019
medline: 28 4 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

Despite widespread use of formalin-fixed, paraffin-embedded (FFPE) tissue in clinical and research settings, potential effects of variable tissue processing remain largely unknown. To elucidate molecular effects associated with clinically relevant preanalytical variability, the National Cancer Institute initiated the Biospecimen Preanalytical Variables (BPV) program. The BPV program, a well-controlled series of systematic, blind and randomized studies, investigated whether a delay to fixation (DTF) or time in fixative (TIF) affects the quantity and quality of DNA and RNA isolated from FFPE colon, kidney, and ovarian tumors in comparison to case-matched snap-frozen controls. DNA and RNA yields were comparable among FFPE biospecimens subjected to different DTF and TIF time points. DNA and RNA quality metrics revealed assay- and time point-specific effects of DTF and TIF. A quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was superior when assessing RNA quality, consistently detecting differences between FFPE and snap-frozen biospecimens and among DTF and TIF time points. RNA Integrity Number and DV DNA and RNA quality may be adversely affected in some tumor types by a 12-hour DTF or a TIF of 72 hours. Results presented here as well as those of additional BPV molecular analyses underway will aid in the identification of acceptable delays and optimal fixation times, and quality assays that are suitable predictors of an FFPE biospecimen's fit-for-purpose.

Identifiants

DOI: 10.5858/arpa.2018-0172-OA PMID: 30785788
pubmed: 30785788
doi: 10.5858/arpa.2018-0172-OA
doi:

Substances chimiques

RNA 63231-63-0
DNA 9007-49-2

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1106-1118

Auteurs

Latarsha J Carithers (LJ)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Rachana Agarwal (R)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Ping Guan (P)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Hana Odeh (H)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Michael C Sachs (MC)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Kelly B Engel (KB)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Sarah R Greytak (SR)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Mary Barcus (M)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Conrado Soria (C)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Chih-Jian Jason Lih (CJ)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

P Mickey Williams (PM)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Philip A Branton (PA)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Leslie Sobin (L)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Benjamin Fombonne (B)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Therese Bocklage (T)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Chris Andry (C)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Elizabeth R Duffy (ER)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Gabriel Sica (G)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Rajiv Dhir (R)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Scott Jewell (S)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Nancy Roche (N)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Helen M Moore (HM)

From Biorepositories and Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland (Drs Carithers, Guan, Odeh, Sachs, Branton, and Moore); Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland (Drs Agarwal, Barcus, Lih, Williams, Sobin, Roche, and Mr Soria); Preferred Solutions Group, Preferred Scientific Group, Washington, District of Columbia (Dr Engel); Kelly Government Solutions, Kelly Services, Rockville, Maryland (Dr Greytak and Mr Fombonne); the Department of Pathology, University of New Mexico, Albuquerque (Dr Bocklage); the Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, Massachusetts (Dr Andry and Ms Duffy); the Department of Pathology and Laboratory Medicine, Emory University, Winship Cancer Institute, Atlanta, Georgia (Dr Sica); the Department of Pathology, University of Pittsburg, Pittsburgh, Pennsylvania (Dr Dhir); and Van Andel Research Institute, Pathology and Biorepository Core, VARI Core Technologies and Services, Grand Rapids, Michigan (Dr Jewell).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Tumeurs de l'intestin › Tumeurs du côlon › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Techniques d'investigation › Conservation biologique › Cryoconservation › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Gouvernement › Agences gouvernementale américaines › Department of Health and Human Services (USA) › Public Health Service (USA) › National Institutes of Health (USA) › National Cancer Institute (USA) › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Techniques histologiques › Techniques de préparation histocytologique › Inclusion de tissu › Inclusion en paraffine › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Phase pré-analytique › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Contrôle de qualité › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › Réaction de polymérisation en chaine en temps réel › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Manipulation d'échantillons › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Techniques histologiques › Techniques de préparation histocytologique › Fixation tissulaire › The Biospecimen Preanalytical Variables...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › The Biospecimen Preanalytical Variables...